UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~October~~November 215, 2025

AVANOS MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-36440

46-4987888

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

5405 Windward Parkway

Suite 100 South

Alpharetta,

Georgia

30004

(Address of principal executive offices)

(Zip code)

Registrant’s telephone number, including area code: (844) 428-2667

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol~~(s)~~			Name of ~~each~~ exchange on which registered
Common Stock - $0.01 Par Value			AVNS			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ~~(§230.405 of this chapter)~~ or Rule 12b-2 of the Securities Exchange Act of 1934 ~~(§240~~.~~12b-2 of this chapter).~~

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 52.02 ~~Departure~~Results of ~~Directors~~Operations orand ~~Certain~~Financial ~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Condition

On ~~October 21~~November 5, 2025, Avanos Medical, Inc. (the “Company”) ~~eliminated~~issued ~~the~~a ~~positions~~press ofrelease ~~Chief~~announcing ~~Commercial~~its ~~Officer~~results ~~and General Counsel, effective December 1, 2025, in connection with a broader organizational restructuring~~ of ~~the~~operations ~~Company.~~for ~~The Company notified Kerr Holbrook,~~ the ~~Company’s~~three ~~Senior Vice President~~ and ~~Chief~~nine ~~Commercial~~months ~~Officer,~~ended ~~and~~September ~~Mojirade James~~30, ~~the~~2025. ~~Company’s~~A ~~Senior~~copy ~~Vice President, General Counsel and Secretary,~~ of the ~~termination~~press ofrelease ~~their~~is ~~employment~~furnished ~~with~~herewith ~~the Company effective December 1, 2025~~ as aExhibit ~~result of the elimination of their positions~~99. ~~The responsibilities previously associated with their roles will be allocated among other Company employees~~1.

The ~~terminations~~information ofcontained ~~each~~in ofItem Mr2.02 ~~Holbrook and Ms. James constitute a qualifying termination under the terms~~ of ~~the~~this ~~Company’s~~Current ~~existing Severance Pay Plan~~Report, asincluding ~~amended~~Exhibit ~~and restated (the “Severance Pay Plan”)~~99. ~~Pursuant to the Severance Pay Plan, the Company will pay Mr. Holbrook a severance payment of $~~1~~,535,417~~ ~~and~~attached ~~Ms. James a severance payment of $1~~hereto,~~425,665.~~ ~~The~~is ~~Company~~being ~~will~~furnished ~~also pay 100% of Mr. Holbrook’s~~ and ~~Ms.~~shall ~~James’s~~not ~~monthly~~be ~~COBRA~~deemed ~~premiums~~“filed” for athe ~~period~~purposes of ~~twelve~~Section ~~months.~~18 ~~The~~of ~~Compensation Committee has also approved~~ the ~~treatment~~Securities ofExchange ~~all~~Act of ~~Mr. Holbrook’s and Ms. James’s unvested awards granted under the Company’s 2021 Long-Term Incentive Plan~~1934, as amended, as(the if“Exchange ~~they had retired. Accordingly~~Act”), ~~all~~or ofotherwise ~~Mr.~~subject ~~Kerr’s and Ms. James’s time-based restricted stock units will vest pro rata, based on the number of days during the restricted period prior~~ to ~~termination of employment, and their performance-based restricted stock units will vest at~~ the ~~end~~liabilities of ~~the~~that ~~relevant performance period based on the Company’s actual performance against the relevant performance goals~~Section. InThe ~~addition,~~information ~~Mr.~~in ~~Holbrook’s~~Item ~~and Ms~~2.02 ~~James’s stock options will remain exercisable for five years following the termination~~ of ~~their~~this ~~employment~~Current (Report or ~~until~~Exhibit ~~their normal expiration date, if earlier)~~99. ~~Further,~~1 ~~the~~shall ~~Compensation~~not ~~Committee~~be ~~approved~~incorporated ~~payment~~by toreference ~~Mr.~~into ~~Holbrook~~any ~~and~~registration ~~Ms.~~statement ~~James~~or ofother ~~their~~document ~~prorated~~pursuant ~~bonuses for 2025, which will assume achievement of the relevant performance goals at target. The above-described payments and benefits~~ to ~~each of Mr. Holbrook and Ms. James are conditioned upon: (i)~~ the ~~execution~~Securities byAct ~~such executive~~ of a1933, ~~separation~~as ~~agreement~~amended, ~~that~~or ~~is consistent with~~ the ~~above-described~~Exchange ~~terms;~~Act, ~~(ii)~~except ~~the~~as ~~execution~~otherwise ~~and~~expressly ~~non-revocation~~stated ofin ~~a general release of claims against the Company for~~ such executive’s employment period; and (iii) such executive’s continued compliance with the terms of his or her Confidentiality, Non-Solicitation and Assignment of Business Ideas Agreement with the Companyfiling.

Item 9.01 Financial Statements and Exhibits

(d)Exhibits.

Exhibit No.						Description
99.1						Press release issued by Avanos Medical, Inc. on November 5, 2025
104						Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AVANOS MEDICAL, INC.

Date:

~~October~~November 235, 2025

By:

/s/ John J. Hurley

John J. HurleyController

John J. HurleyController(Principal Accounting Officer)

Filing Compare · AVANOS MEDICAL, INC.